SCHEMBL15501699

SCHEMBL15501699

Cc1cc(N)c(C(C)(C)C)cc1C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.42
TSHR P16473 4/20 0.42
MAPK1 P28482 2/20 0.42
POLB P06746 2/20 0.41
CD44 P16070 1/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ALDH1A1 P00352 8/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
CA2 P00918 2/20 0.36
TYR P14679 1/20 0.36
ALOX15 P16050 2/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ATP2A2 P16615 1/20 0.35
ATP2A3 Q93084 1/20 0.35
TDP1 Q9NUW8 4/20 0.33
TP53 P04637 2/20 0.33
HIF1A Q16665 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22367815 0.87 CYP3A4 (0.50) CYP3A4TSHRMAPK1POLBCD44
SCHEMBL10385743 0.85 CYP3A4 (0.55) CYP3A4TSHRMAPK1POLBCD44
SCHEMBL560086 0.84 PTK2 (0.41) TSHRPOLBCYP1A2CYP2C9CYP2C19
SCHEMBL2153631 0.81 ALDH1A1 (0.43) CYP3A4TSHRMAPK1POLBCYP1A2
SCHEMBL27489165 0.81 CYP2C9 (0.44) CYP3A4TSHRMAPK1POLBCYP1A2
SCHEMBL24116135 0.80 CYP3A4 (0.55) CYP3A4TSHRMAPK1POLBCYP1A2
SCHEMBL168392 0.80 CYP3A4 (0.48) CYP3A4TSHRMAPK1POLBCYP1A2
SCHEMBL30301248 0.80 CYP3A4 (0.48) CYP3A4TSHRMAPK1POLBCYP1A2
SCHEMBL7642566 0.79 CYP3A4 (0.37) CYP3A4TSHRMAPK1POLBCD44
SCHEMBL15927489 0.79 CYP3A4 (0.42) CYP3A4TSHRMAPK1POLBCD44

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3344249-B1 PROCESSES FOR THE PREPARATION OF IVACAFTOR LAURUS LABS LTD (IN) 2020-10-28 EP disclosed
WO-2016181414-A1 PROCESS FOR THE SYNTHESIS OF IVACAFTOR AND RELATED COMPOUNDS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-11-17 WO disclosed
US-9090619-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-07-28 US disclosed
US-9051324-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-06-09 US disclosed
US-20140343315-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED 2014-11-20 US disclosed
US-20140073653-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343315-A1 Modulators of ATP-Binding Cassette Transporters CFTR, ABCB1, ABCC2 CYP3A4 1862/4885TSHR 2753/4885MAPK1 4329/4885
US-20140073653-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, ABCB1, ABCC4 CYP3A4 1240/4885TSHR 1553/4885MAPK1 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.